|
Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...
Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....
New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...
|
|
|
|
Risk of Liver and Other Types of Cancer in Patients With
Cirrhosis:
A Nationwide Cohort Study in Denmark
|
| table 1.
Descriptive Characteristics of 11,605 1-Year Survivors With
Cirrhosis in Denmark, 1977-1989 |
|
| Characteristics |
Type of
Cirrhosis
|
Alcoholic
|
Primary Biliary
|
Chronic
Hepatitis
|
Nonspecified
|
| Men |
Women |
Men |
Women |
Men |
Women |
Men |
Women |
|
| No. of patients |
5,079 |
2,086 |
57 |
263 |
712 |
978 |
1,210 |
1,220 |
| Person-years at risk |
28,801 |
12,508 |
374 |
1,777 |
5,466 |
7,494 |
6,666 |
7,208 |
| Average age at discharge with cirrhosis (yr) |
51.8 |
52.5 |
57.9 |
60.5 |
43.4 |
55.1 |
57.5 |
61.7 |
| Mean follow-up time (yr) |
5.7 |
6.0 |
6.5 |
6.7 |
7.7 |
7.7 |
5.5 |
5.9 |
|
|
Return
To Article
|
|
|
